Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma–Associated Herpesvirus-Infected Endothelium

Yehoshua Maor¹,*, Jinlong Yu¹,*, Paula M. Kuzontkoski¹, Bruce J. Dezube², Xuefeng Zhang¹, and Jerome E. Groopman¹

Submitted 23-Apr-2012; accepted 11-Oct-2012

Abstract
Kaposi sarcoma is the most common neoplasm caused by Kaposi sarcoma–associated herpesvirus (KSHV). It is prevalent among the elderly in the Mediterranean, inhabitants of sub-Saharan Africa, and immunocompromised individuals such as organ transplant recipients and AIDS patients. Current treatments for Kaposi sarcoma can inhibit tumor growth but are not able to eliminate KSHV from the host. When the host’s immune system weakens, KSHV begins to replicate again, and active tumor growth ensues. New therapeutic approaches are needed. Cannabidiol (CBD), a plant-derived cannabinoid, exhibits promising antitumor effects without inducing psychoactive side effects. CBD is emerging as a novel therapeutic for various disorders, including cancer. In this study, we investigated the effects of CBD both on the infection of endothelial cells (ECs) by KSHV and on the growth and apoptosis of KSHV-infected ECs, an in vitro model for the transformation of normal endothelium to Kaposi sarcoma. While CBD did not affect the efficiency with which KSHV infected ECs, it reduced proliferation and induced apoptosis in those infected by the virus. CBD inhibited the expression of KSHV viral G protein–coupled receptor (vGPCR), its agonist, the chemokine growth-regulated protein α (GRO-α), vascular endothelial growth factor receptor 3 (VEGFR-3), and the VEGFR-3 ligand, vascular endothelial growth factor C (VEGF-C). This suggests a potential mechanism by which CBD exerts its effects on KSHV-infected endothelium and supports the further examination of CBD as a novel targeted agent for the treatment of Kaposi sarcoma.

Keywords:
cannabidiol, Kaposi sarcoma, Kaposi sarcoma–associated herpesvirus, viral G protein–coupled receptor, vascular endothelial growth factor receptor 3

Introduction
Kaposi sarcoma–associated herpesvirus (KSHV), also termed human herpesvirus 8 (HHV-8), is the etiological agent of Kaposi sarcoma, a vascular neoplasm.⁴ KSHV usually establishes a lifelong latent infection in the host, additional factors, including immunosuppression, can facilitate the transformation of infected cells into an active malignancy.⁴ KSHV produces a set of viral proteins that promote its survival and spread. These proteins can co-opt normal cellular receptors to facilitate viral entry into target cells, mimic cellular receptors to evade the immune system, and foster tumor cell proliferation.⁵

One such viral protein, KSHV viral G protein–coupled receptor (vGPCR), is believed to be a key contributor to malignant transformation because it can immortalize endothelial cells⁶ and induce Kaposi sarcoma–like lesions in a transgenic animal model.⁵ KSHV viral G protein–coupled receptor (vGPCR) is constitutively active. In vitro, it can be detected in target cells during lytic infection.¹¹ It is also expressed in scattered tumor cells within Kaposi sarcoma lesions.¹² vGPCR is highly homologous to the human CXC chemokine receptors CXCR1 and CXCR2,¹⁴,¹⁵ and ligands of these receptors, including interleukin-8 (IL-8) and growth-regulated protein α (GRO-α), can augment the effects of vGPCR.¹⁶,¹⁷ Although some cellular G protein–coupled receptor kinases may inhibit vGPCR to a small degree,¹⁸ and chemokines such as interferon γ–induced protein 10 (IP-10)¹⁹ and stromal cell–derived factor 1α (SDF-1α) have been reported to inhibit vGPCR signaling,²⁰ no effective means to block the effects of vGPCR have advanced to clinical use.

Cannabidiol (CBD) was first isolated in 1940.²¹ It is a major component of the plant Cannabis sativa, which is also the source of Δ⁹-tetrahydrocannabinol (Δ⁹-THC).²² Due to its multiple biological activities, CBD has been

¹Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
²Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
*The first 2 authors contributed equally to this work.

Corresponding Author:
Jerome E. Groopman, Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, RN-325D, Boston, MA 02215, USA
(Email: jgroopma@bidmc.harvard.edu).
identified as a potential clinical agent. Moreover, CBD affects these activities without the psychoactive side effects that typify Δ⁹-THC. Recent studies have documented the potential antitumorigenic properties of CBD in the treatment of various neoplasms, including breast cancer, lung cancer, bladder cancer, glioblastoma, and leukemia. CBD induces these effects through a variety of mechanisms and signaling pathways. For example, it inhibits the growth and metastasis of breast cancer by downregulating the expression of inhibitor of differentiation 1 (ID-1), which limits the invasion of lung cancer cells into adjacent tissues by reducing plasminogen activator inhibitor (PAI-1) levels, and induces the programmed cell death of bladder cancer cells by affecting a continuous calcium influx. In addition, CBD can enhance the inhibitory properties of Δ⁹-THC on the growth and survival of glioblastoma cell lines; however, the precise molecular mechanisms by which CBD mediates these effects are poorly understood.

KSHV-infected endothelial cells are commonly used as an in vitro model for Kaposi sarcoma. We used primary human dermal microvascular endothelial cells (HMVECs) to assess the effects of CBD on infection, proliferation, and programmed cell death. CBD inhibited proliferation and enhanced apoptosis in KSHV-infected HMVECs by blocking the expression of vGPCR, GRO-α, vascular endothelial growth factor receptor 3 (VEGFR-3), and vascular endothelial growth factor C (VEGF-C). These data support the further evaluation of CBD as a novel therapeutic to treat Kaposi sarcoma.

**Results**

**CBD does not modulate the infection of HMVECs by KSHV.** CBD can alter vascular permeability and therefore may affect viral entry into endothelial cells. To investigate whether CBD may enhance KSHV infection of endothelial cells, we exposed HMVECs to green fluorescent protein (GFP)-tagged KSHV or to a mock infection in the presence of various concentrations of CBD. Under control conditions (0 µM CBD), KSHV infected an average of 25% of HMVECs per well (Fig. 1). We observed no significant difference in infection efficiency when the cells were pretreated with up to 10 µM CBD (Fig. 1). These data suggest that CBD does not modulate the infection of endothelial cells by KSHV.

**CBD preferentially inhibits the proliferation of KSHV-infected HMVECs versus normal HMVECs.** Recent studies have indicated various antitumorigenic properties of CBD, including the inhibition of proliferation in breast cancer and glioblastoma cells. This prompted us to assess the effects of CBD on the growth of mock-infected HMVECs and KSHV-infected HMVECs (KSHV/HMVEC), models for normal endothelium and nascent Kaposi sarcoma, respectively, using an MTS-based assay. This assay measures changes in metabolic activity as a reflection of changes in proliferation and/or survival. We found a decrease in the percentage of proliferating mock-infected cells when treated with CBD at concentrations between 2.5 and 10 µM; however, even at 10 µM CBD, proliferation was reduced by only 20% of the controls (Fig. 2A). At concentrations between 1.5 and 10 µM, CBD inhibited significantly more proliferation in the virus-infected HMVECs (IC₅₀ = 2.08 µM) than in the mock-infected HMVECs (Fig. 2A and 2B). In fact, at 10 µM, CBD reduced proliferation in the virus-infected cells by 79% of the controls (Fig. 2A). These data suggest that at select concentrations, CBD preferentially inhibits the proliferation of KSHV-infected endothelium versus normal endothelium.

**CBD preferentially induces apoptosis in KSHV-infected HMVECs versus normal HMVECs.** Previous studies have shown that CBD induces apoptosis in various tumor cells. Using mock-infected HMVECs and KSHV-infected HMVECs, we assessed the differential effects of CBD on programmed cell death. While CBD induced dose-dependent apoptosis in both cell types, at 0.25 to 1.0 µM, CBD induced significantly more cell death in the virus-infected HMVECs than in the mock-infected HMVECs (Fig. 3A). In the virus-infected cells, the in vitro EC₅₀ for CBD was 1.04 µM (Fig. 3B), while the EC₅₀ of the mock-infected cells was calculated as 1.68 µM. When treated with 2.0 to 10 µM CBD, there was no significant difference in apoptosis between the 2 cell types (Fig. 3A). At these higher concentrations, CBD induced between 80% and 100% apoptosis in both mock- and virus-infected cells (Fig. 3A). These dose-response data indicate that endothelial cells infected with KSHV are more sensitive to CBD-induced apoptosis than mock-infected endothelium and suggest that at specific concentrations, CBD may preferentially kill Kaposi sarcoma tumor cells versus normal endothelium.
CBD inhibits the expression of KSHV vGPCR. To explore the mechanism(s) by which CBD inhibits the growth of KSHV/HMVECs and induces their programmed cell death, we examined the effect of CBD on KSHV vGPCR, a protein that immortalizes endothelial cells and promotes Kaposi sarcoma tumorigenesis.7,9 vGPCR facilitates the transformation of KSHV-infected cells and enhances the proliferation of KSHV-infected endothelium.8,10 To confirm that vGPCR is expressed in Kaposi sarcoma, we examined protein levels and localization in Kaposi sarcoma lesions by immunohistochemical analysis. We found vGPCR expression in irregular vascular formations and scattered spindle cells of the Kaposi sarcoma tumor sections (Fig. 4A, panels II and III). Lack of staining in the isotype control–treated section illustrates antibody specificity (Fig. 4A, panel I).

In an earlier publication, we demonstrated that at low doses, Δ²-THC, a psychoactive cannabinoid related to CBD, enhanced the expression of vGPR in KSHV-infected HMVECs.15 Here, by Western blot analysis, we examined the effects of CBD on the expression of vGPCR in such cells. We found that CBD altered vGPCR expression in KSHV-infected HMVECs; however, in contrast to Δ²-THC, CBD induced dose-dependent inhibition (Fig. 4B). Moreover, the concentrations at which CBD preferentially induced apoptosis and reduced proliferation in the KSHV/HMVECs were those at which vGPCR expression was also inhibited in these cells (Figs. 2, 3, and 4B). This suggests a potential mechanism through which CBD exerts its anticancer effects in KSHV-associated neoplasms.
Effect of cannabidiol on KSHV-infected endothelial cells / Maor et al.

CBD downregulates the expression of VEGFR-3 and VEGF-C.
Upon activation, the VEGFR-3 receptor, a key molecule for lymphangiogenesis, promotes KSHV-induced infection, growth, and transformation of endothelial cells. To examine the activation status of VEGFR-3, we transiently transfected a vGPCR expression plasmid or vector control into a stable 293 cell line, manipulated to express high levels of VEGFR-3 (293/VEGFR-3). We immunoprecipitated VEGFR-3 from whole cell lysates and subsequently performed Western blot analysis with a phosphotyrosine antibody (Fig. 6A). We observed significant tyrosine phosphorylation in the cells transfected with vGPCR (+) as compared to those transfected with the vector control (−) (Fig. 6A). To confirm these observations in a primary cell line with endogenous VEGFR-3 expression, we repeated the experiment in HMVECs. Similarly, we observed significantly greater VEGFR-3 activation in the HMVECs transfected with vGPCR as compared to those transfected with the vector control (Fig. 6B). Taken together, these data indicate that vGPCR activates VEGFR-3 in 293/VEGFR-3 cells as well as in primary endothelial cells. When we examined total VEGFR-3 levels in KSHV-infected HMVECs, we observed high levels of the protein under control conditions (Fig. 6C, lane 0). This is consistent with existing data that demonstrate the enhancement of VEGFR-3 expression by KSHV and with high endogenous expression of VEGFR-3 in Kaposi sarcoma. Upon treatment with various concentrations of CBD, VEGFR-3 levels were significantly reduced (Fig. 6C), suggesting another mechanism whereby CBD may affect the proliferation and viability of Kaposi sarcoma through the VEGFR-3 signaling pathway.

Next, by ELISA, we examined levels of VEGF-C and VEGF-D, the cognate ligands of VEGFR-3, in the conditioned media of KSHV/HMVECs after treatment with various concentrations of CBD (Fig. 7). We observed a significant dose-dependent decrease in VEGF-C levels in the conditioned media (Fig. 7A), with an in vitro IC₅₀ of 7.87 µM (Fig. 7B); however, CBD had no effect on VEGF-D expression (Fig. 7C). These data demonstrate that CBD inhibits the expression of VEGF-C in KSHV/HMVECs, while VEGF-D levels remain very low with/without CBD treatment. These data are consistent with CBD-induced reduction of VEGFR-3 levels (Fig. 6C), and together, they suggest that CBD may be an inhibitor of VEGFR-3/VEGF-C signaling in Kaposi sarcoma.

Discussion
CBD has been evaluated clinically for the treatment of various conditions, including anxiety, psychosis, and pain. In contrast to other members of the cannabinoid family, CBD has a strong safety profile and induces no psychotropic effects. Therefore, it has become an attractive agent in the search for newanticancer therapies. Our current study demonstrated that CBD preferentially enhanced apoptosis and inhibited the proliferation of KSHV-infected endothelial cells. This selective targeting of KSHV-induced neoplasia suggests that CBD may have a desirable therapeutic index when used to treat cancer. Moreover, a recent study demonstrated that CBD can be delivered effectively by nasal and transdermal routes, which may be particularly valuable for the treatment of Kaposi sarcoma oral or skin lesions.

The molecular mechanisms by which CBD exerts its therapeutic effects are not fully understood, although CBD has been shown to act as an inverse agonist of the cannabinoid receptors CB1 and CB2. We found that CBD reduced the levels of vGPCR, GRO-α, VEGFR-3, and VEGF-C in KSHV-infected endothelium. These proteins are believed to play important roles in the initiation, growth, metastasis, and survival of Kaposi sarcoma.
vGPCR is lytically expressed in Kaposi sarcoma lesions but not in normal endothelium.\(^{15}\) It is presumed to be paramount in the transformation of normal cells to KSHV-associated cancers.\(^{5}\) Also, vGPCR promotes the growth of Kaposi sarcoma and helps to protect endothelial cells from programmed cell death.\(^{10,49}\) Although vGPCR is a constitutively active receptor, GRO-\(\alpha\) is one of the ligands that can enhance its effects.\(^{17}\) GRO-\(\alpha\) also plays an important role in wound healing, inflammation, angiogenesis, and tumorigenesis.\(^{50}\) Its transcripts increase in abundance with age in many human tissues, particularly the skin,\(^{51}\) and therefore, its inhibition may be of relevance for the treatment of classic age-related Kaposi sarcoma.\(^{52}\)

VEGF-C and its receptor, VEGFR-3, are closely associated with tumorigenesis and tumor lymphatic metastasis.\(^{23,34}\) Kaposi sarcoma is believed to be derived from KSHV-infected lymphatic endothelial cells that express high levels of VEGF-C and VEGF-3.\(^{30,41}\) VEGF-C/VEGF-3 signaling modulates KSHV-induced transformation and growth of endothelial cells.\(^{37}\) Moreover, KSHV vGPCR can enhance endothelial cell transformation through activation of VEGFR-2 and VEGFR-3.\(^{55}\) Therefore, targeting the VEGFR-3 signaling pathway with CBD presents a potential means to treat highly vascularized tumors like Kaposi sarcoma.

We demonstrated that at higher experimental concentrations, that is, 2.5 to 10 \(\mu\)M, CBD inhibited the expression of VEGF-C in KSHV-infected endothelial cells. CBD significantly inhibited the expression of GRO-\(\alpha\) beginning at a lower experimental concentration (1.0 \(\mu\)M) and with a lower overall IC\(_{50}\) (1.66 \(\mu\)M v. 7.87 \(\mu\)M). The varying efficacies with which CBD inhibited GRO-\(\alpha\) and VEGF-C may be due to different forms of regulation at the transcriptional and/or

---

**Figure 5.** CBD reduces levels of GRO-\(\alpha\) in media conditioned by KSHV-infected HMVECs. (A) GRO-\(\alpha\) and (C) IL-8 levels in KSHV/HMVEC-conditioned media as assayed by ELISA. After KSHV/HMVECs were incubated with various CBD concentrations or a vehicle control for 18 hours, GRO-\(\alpha\) (A) and IL-8 levels (C) were measured by ELISA. Data represent the mean ± SD. \(*P < 0.05, \**P < 0.01, \**P < 0.001 for CBD treatments versus a control (0 \(\mu\)M CBD). (B) Regression analysis of the effect of CBD on GRO-\(\alpha\) expression in KSHV/HMVEC-conditioned media.

**Figure 6.** VEGFR-3 is activated by KSHV vGPCR and inhibited by CBD. (A) VEGFR-3 activation as assayed by VEGFR-3 immunoprecipitation and Western blot analysis. 293/VEGFR-3 cells were transfected with a KSHV vGPCR expression plasmid (+) or an empty vector (−). Total cell lysates were collected 48 hours after transfection and used for VEGFR-3 immunoprecipitation. Tyrosine phosphorylation of VEGFR-3 was detected by Western blot analysis. Total VEGFR-3 was used as a loading control. (B) VEGFR-3 activation as assayed by VEGFR-3 immunoprecipitation and Western blot analysis in HMVECs. HMVEC cells were transfected with a KSHV vGPCR expression plasmid (+) or an empty vector (−) and assayed as in A. (C) VEGFR-3 expression by Western blot analysis in KSHV/HMVECs. KSHV/HMVECs were incubated with various CBD concentrations for 18 hours. Total cell lysates were collected and VEGFR-3 expression measured by Western blot analysis. GAPDH was used as a loading control.
translational levels; however, further study is required to characterize the specific molecular mechanisms responsible. In adults, VEGFR-3 is predominantly expressed by lymphatic endothelium and tumor vasculature and by a subset of normal endothelial cells, including HMVECs. As such, CBD could be expected to affect normal endothelial cells at higher concentrations. In contrast, the GRO-α receptor, vGPCR, is not expressed by normal endothelial cells. Based on these data, we hypothesize that while higher concentrations of CBD may target the expression of both VEGF-C and GRO-α, lower concentrations of CBD could significantly impact the proliferation and apoptosis of KSHV-infected cells and spare normal endothelium (as shown in Figs. 2A and 3A) by predominantly targeting signaling through GRO-α and vGPCR.

With the advent of highly active antiretroviral therapy for the treatment of AIDS in the 1990s, the incidence of AIDS-associated Kaposi sarcoma has decreased. However, the number of patients living with AIDS continues to increase, and as they live longer, it is likely that AIDS-associated Kaposi sarcoma will also rise. New treatments are needed to prevent or control the disease. Our data support the evaluation of CBD as a novel target-specific therapeutic for KSHV-infected neoplasms, including Kaposi sarcoma. We demonstrated that CBD could preferentially induce apoptosis and attenuate the proliferation of KSHV-infected HMVECs by inhibiting the expression of vGPCR, GRO-α, VEGFR-3, and VEGF-C. Further investigation to elucidate more precisely the mechanisms by which CBD induces its inhibitory effects may help guide the development of CBD as a treatment for KSHV-associated neoplasia.

**Materials and Methods**

**Cells.** Primary HMVECs (adult) were purchased from Lonza (Allendale, NJ) and maintained in EBM-2 basal medium, supplemented with EGM-2 MV BulletKit (Lonza). GFP–BCBL-1 cells were a gift from Dr. Jeffrey Vieira (Department of Laboratory Medicine, University of Washington, Seattle, WA). They were maintained in RPMI 1640 medium and supplemented as described previously. The 293/VEGFR-3 cell line (Genentech, South San Francisco, CA) was maintained in DMEM with 10% FBS.

**Reagents.** CBD was purchased from Tocris Bioscience (Ellisville, MO). TPA was purchased from Sigma-Aldrich (St. Louis, MO). Anti–KSHV vGPCR antibody was purchased from Cell Sciences (Canton, MA). All other antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).

**Plasmids and transfections.** The KSHV vGPCR expression plasmid (pcDNA3.1vGPCR) was constructed as follows: KSHV genomic DNA was extracted from KSHV-positive BCBL-1 cells. The vGPCR gene was amplified from the KSHV genomic DNA, using the primers purchased from Invitrogen (Carlsbad, CA) (upstream sequence: 5′-GGAATTCATGGCGGCCGACCATTTCC-3′; downstream sequence: 5′-GTCTAGACGTGGTGGCGCCGGA- CATG-3′). The purified PCR product was digested with EcoR I and Xba I and inserted into the pcDNA3.1 plasmid digested with same restriction endonucleases to create pcDNA3.1vGPCR. HMVECs and 293/VEGFR-3 cells were transiently transfected with pcDNA3.1vGPCR or a vector control (pcDNA3.1) using Superfect Transfection Reagent from Qiagen (Valencia, CA).

**Kaposi sarcoma tissue samples.** Tissue samples from Kaposi sarcoma skin lesions of diagnosed HIV-positive patients were obtained after informed consent at Beth Israel...
Deaconess Medical Center (BIDMC). The protocol and consent form were approved by the BIDMC review board in accordance with an assurance filed with and approved by the US Department of Health and Human Services.

**Immunohistochemistry.** Kaposi sarcoma tissue samples were fixed in 4% formaldehyde solution and paraffin embedded. Serial sections were prepared by the Dana-Farber/ Harvard Cancer Center Research Pathology Core (Boston, MA). Immunohistochemical staining was performed per instructions from Upstate Biotechnology (Waltham, MA). Kaposi sarcoma tissue sections were observed under a Zeiss LSM 510 META upright confocal microscope (Oberkochen, Germany).

**GFP-KSHV virus propagation and infection.** GFP–BCBL-1 cells were grown to a density of 5 × 10⁵ cells/mL, induced with TPA at 20 ng/mL, and grown for 5 days. To harvest the virus, cells were pelleted at 500g for 15 minutes. The supernatant was removed and centrifuged at 15,000g for 4 hours. The pellet was resuspended in 1/100 growth volume complete media as discussed previously and centrifuged at 300g for 5 minutes. Purified KSHV virion was titrated by real-time PCR as described previously.

Sixty-percent confluent HMVECs were pretreated for 2 hours with various CBD concentrations or a vehicle control. Subsequently, they were either mock infected or infected with GFP-KSHV in 24-well plates at 37°C for 3 hours, washed, and incubated at 37°C for 2 days in HMVEC medium, as described above. KSHV infections were performed at a multiplicity of infection of 5 to 6 KSHV copies per cell. Green fluorescent cells were counted under a fluorescent microscope (200× magnification) (Diaphot 300, Nikon, Tokyo, Japan) or detached by 5 mM EDTA in PBS and analyzed on a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) to determine the percentage of cells infected.

**Cell stimulation, immunoprecipitation, and Western blot analysis.** Cells were starved for 2 hours in serum-free media and subsequently stimulated with various concentrations of CBD as indicated in 0.5% BSA media for 24 hours (unless otherwise noted). After stimulation, total cell lysates were collected and processed for immunoprecipitation and Western blot analysis as described previously.

**Proliferation assay.** The proliferation assay was performed using CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS, Promega, Madison, WI) per the manufacturer’s instructions. The number of proliferating cells was calculated as a percentage of total cells.

**Apoptosis assay.** KSHV-infected and mock-infected HMVECs were incubated in 0.5% BSA media with various concentrations of CBD (0-10 µM) for 24 hours. The In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Science, Mannheim, Germany) was used for the detection and quantification of apoptosis. Cells were stained by the TUNEL method and observed under a fluorescent microscope to determine double-stranded DNA breaks per the manufacturer’s instructions.

**Cytokine ELISA.** Media conditioned by KSHV/HMVEC cells treated with various concentrations of CBD were collected and assayed by ELISA per the manufacturer’s instructions as follows: IL-8 (Human CXCL8/IL-8 Immunoassay, R&D Systems, Minneapolis, MN), GRO-α (Human CXCL1/GRO-α Immunoassay, R&D Systems), VEGF-D (Human VEGF-D Immunoassay, R&D Systems), and VEGF-C (Human VEGF-C Assay Kit, IBL-America, Minneapolis, MN).

**Statistical analysis.** Statistical significance was determined using the Student 2-tailed t test. Data represent the mean ± SD of at least 3 independent experiments, with P < 0.05 considered statistically significant. To calculate the IC₅₀ and EC₅₀ values, regression analyses were performed based on the proliferation and apoptosis data and the VEGF-C and GRO-α expression data, respectively. Western blot analysis and immunohistochemistry were repeated at least 3 times, and representative blots or images are shown.

**Declaration of Conflicting Interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received the following financial support for the research, authorship, and/or publication of this article: This work was supported by divisional funds.

**References**


